MedinCell Announces the Initiation of Coverage of Its Stock by ODDO-BHF
MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News:
The initiation of coverage realized by ODDO-BHF on July 20, 2021, with a study entitled “First approval and launch expected in 2022“, strengthens the visibility of the MedinCell (Paris:MEDCL) share among French and international institutional investors.
This coverage comes in addition to those already carried out by the brokerage firms Bryan Garnier and Kepler Cheuvreux.
About MedinCell
MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 140 people representing over 25 different nationalities.
Contacts
MedinCell
David Heuzé
Head of communication
[email protected]
+33 (0)6 83 25 21 86
NewCap
Louis-Victor Delouvrier
Relations investisseurs
[email protected]
+33 (0)1 44 71 94 94
NewCap
Nicolas Merigeau
Media Relations
[email protected]
+33 (0)1 44 71 94 94
